Xtant Medical to Announce Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026
Rhea-AI Summary
Xtant Medical (NYSE American: XTNT) will release fourth-quarter and full-year 2025 financial results before trading on Tuesday, March 31, 2026. A conference call with CEO Sean Browne and CFO Scott Neils is scheduled for 8:30 AM ET that day.
Investors can join by dial-in or webcast; a replay will be posted under "Investor info" on the company's website after the live call.
Positive
- None.
Negative
- None.
News Market Reaction – XTNT
In the Mar 25 session, XTNT gained 0.55%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 02 | Divestiture proceeds update | Positive | +0.2% | Final Companion Spine payment lifted total Coflex and Paradigm divestiture proceeds. |
| Feb 25 | Conference participation | Neutral | +0.8% | Management participation in Canaccord musculoskeletal conference and investor meetings. |
| Dec 11 | Product launch | Positive | -1.1% | Commercial launch of next‑generation nanOss Strata synthetic bone graft. |
| Dec 01 | Business sale completion | Neutral | +1.8% | Companion Spine completed acquisition of Paradigm Spine assets from Xtant. |
| Dec 01 | Asset divestiture | Positive | +1.8% | Xtant completed sale of non-core Coflex assets and Paradigm OUS entities. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent corporate/divestiture updates and product news generally saw modest positive price reactions, with one product launch drawing a small negative move.
Over the past several months, Xtant reported multiple strategic steps. On Dec 1, 2025, it completed the sale of certain Coflex assets and Paradigm OUS businesses for about $19.2 million, followed by related Companion Spine transactions totaling $21.4 million and a final $10.7 million payment received by Mar 2, 2026. A next‑generation nanOss Strata synthetic bone graft launched on Dec 11, 2025, and management participated in a musculoskeletal conference on Mar 2, 2026. The current earnings date announcement follows this period of portfolio reshaping and product expansion.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Details:
Conference Date: Tuesday, March 31, 2026
Conference Time: 8:30 AM ET
Conference Dial-in: 888-506-0062
International Dial-in: 973-528-0011
Passcode: 581090
Conference Call Name: Xtant Medical Q4 2025 Financial Results
Webcast link: https://www.webcaster5.com/Webcast/Page/3039/53616
Following the live call, a replay will be available on the Company's website, https://xtantmedical.com/, under "Investor info."
About Xtant Medical Holdings, Inc.
Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in
View original content to download multimedia:https://www.prnewswire.com/news-releases/xtant-medical-to-announce-fourth-quarter-and-full-year-2025-financial-results-on-march-31-2026-302724338.html
SOURCE Xtant Medical Holdings, Inc.